The global Plasmid DNA Manufacturing Market is expanding rapidly due to increasing demand for gene therapies, DNA vaccines, cell therapies, mRNA therapeutics, and advanced biologic development. Plasmid DNA serves as an important raw material in viral vector production, genome editing, mRNA manufacturing, and immunotherapy research. Growing clinical-trial activity in oncology and rare genetic disorders, along with increasing outsourcing by biotechnology and pharmaceutical companies, is further supporting market growth.

According to Fortune Business Insights, the global plasmid DNA manufacturing market was valued at USD 2.46 billion in 2025 and is projected to grow from USD 2.92 billion in 2026 to USD 11.60 billion by 2034, exhibiting a CAGR of 18.80% during the forecast period.

Why is the Plasmid DNA Manufacturing Market Growing?

The increasing development of gene therapies, mRNA-based therapeutics, cell therapies, and genome-editing technologies is a major factor driving the market. Plasmid DNA is widely used in viral-vector production and serves as a key component in several advanced therapeutic manufacturing workflows.

Approximately 63% of active gene therapy clinical programs globally utilize plasmid DNA during development and production processes. Growing investment in oncology immunotherapies, rare-disease treatments, personalized medicine, and CRISPR technologies is further increasing demand for high-quality plasmid DNA.

Plasmid DNA manufacturing is increasingly used for:

• Gene therapy development
• DNA vaccine production
• mRNA therapeutic development
• Viral vector manufacturing
• CRISPR genome editing
• CAR-T cell therapy
• Cancer immunotherapy
• Personalized medicine
• Infectious disease therapeutics
• Synthetic biology research

Key Market Trends Shaping Industry Growth

Rising Demand for Gene Therapy and mRNA Therapeutics

The increasing number of gene therapy and mRNA therapeutic programs is creating strong demand for high-purity plasmid DNA. Pharmaceutical and biotechnology companies require reliable plasmid supplies for research, clinical development, and commercial manufacturing.

The expansion of contract development and manufacturing organizations (CDMOs) is also enabling smaller biotechnology companies to access scalable GMP-grade plasmid manufacturing capabilities.